Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration by Year
Contingent consideration — Remaining potential development & regulatory milestones (historical, $M) ($M)
Vertex Pharmaceuticals Contingent consideration: $678M in FY2023, unchanged from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-15) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration — Remaining potential development & regulatory milestones (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 678 | 0.0% | Form 10-K (filed 2024-02-15) ↗ |
| FY2022 | Dec 31, 2022 | 678 | 0.0% | Form 10-K (filed 2023-02-10) ↗ |
| FY2021 | Dec 31, 2021 | 678 | 0.0% | Form 10-K (filed 2022-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 678 | 0.0% | Form 10-K (filed 2021-02-11) ↗ |
| FY2019 | Dec 31, 2019 | 678 | – | Form 10-Q (filed 2026-08-04) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration ($M), annual FY2019–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-rem-milestone
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.